Bayer

Pharmaceuticals
BAYN.DE
€ 64 0.54
Share price
$ 66 bn
Market Cap
$ 103 bn
Enterprise Value

Carbon footprint

31 Ton
GHG emissions per $ 1 mln investment
1.1x the weighted average for S&P 500
FY2021
How is this calculated?
-12%
YOY change in GHG emissions
Stronger than the -8.7% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-3.9%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -5.1% weighted average for S&P 500
FY2022
How is this calculated?

Bayer aims to reduce Scope 1 + 2 by 42% by 2029 from a base year 2019


This target has not been verified as science based according to SBTi
Bayer's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

Secondary Climate Goal

-3.4%
Proj. YOY change in GHG emissions (all Scopes)
Weaker than the -6.9% weighted average for S&P 500
FY2022
How is this calculated?

Bayer aims to achieve net zero for all Scopes by 2050


This target has not been verified as science based according to SBTi
Bayer's actual and proj. GHG emissions (all Scopes) (Kt of CO2e)

GHG emissions and Carbon intensity

Bayer's GHG emissions (market-based) (Kt of CO2e)
Bayer's Carbon intensity (Tons per 1 USDm)

Bayer's carbon footprint

Bayer reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 3,170 Kt (-410 /-11.5% y-o-y). Also positively, carbon intensity declined to 61 t (-13 /-17.9% y-o-y).

Bayer's Scope 3 emissions was down at 8,940 Kt (-260 /-2.8% y-o-y). The rate of decline has slowed compared to the trend since 4Q'19 (CAGR -3.8%).

The company is committed to reducing Scope 1 + 2 by 42% by 2029 from a base year 2019, which translates into the estimated reduction of -124 Kt per annum over the period of FY2022 - FY2029. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Also, the company commits to achieving net zero for all Scopes by 2050, which translates into the estimated reduction of -418 Kt per annum over the period of FY2022 - FY2050. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Also, the company commits to reducing Scope 3 by 12.3% by 2029 from a base year 2019, which it appears to have already achieved as of 2021. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Company environmental metrics

Show more...